Jaipur, Rajasthan – In a swift response to Aaj Tak’s explosive exposé on the rampant trade of fake and substandard drugs in Rajasthan, the Commissioner has ordered a comprehensive investigation into all pending cases to be wrapped up within 15 days, with strict action promised against those responsible. The report, which aired recently, triggered late-night meetings across the health ministry and drug control offices, prompting the central government to demand a detailed report from the state and issue directives for intensified probes.
The Aaj Tak investigation revealed a shocking lapse: Over the past year, 290 medicines were found to be grossly substandard, yet no concrete action was taken against any manufacturing company. Many firms are based outside Rajasthan, leading officials to delay enforcement, while in some instances, half-hearted inquiries were abandoned. In the entire year, the department acted in just three cases. The counterfeit drugs included antibiotics, cardiac medications, painkillers, acidity treatments, anti-allergics, children’s syrups, eye and ear drops, and even injections. Alarmingly, some lacked active ingredients altogether, while others turned out to be bogus veterinary drugs repackaged for human use.
The Commissioner Dr. T. Shubhamangala, addressing a high-level meeting, acknowledged the gravity of the situation, stating, “This appears to be a case of intentional negligence at first glance.” One administrative officer implicated in suppressing investigation files has already been suspended. Shubhamangam further warned, “If collusion with drug companies is proven against any official, legal action will follow.” The meeting resolved to conduct thorough sampling of all batches from every drug manufacturer in the state. For out-of-state firms, Rajasthan officials will personally travel for on-site inspections to ensure no stone is left unturned.
This “poisonous business” of fake drugs has played havoc with public health, exposing deep flaws in Rajasthan’s drug regulation system. Critical medications like antibiotics and cardiac drugs pose severe risks when adulterated, potentially leading to life-threatening complications. While the probe’s momentum offers hope for accountability, questions linger on whether this will translate into real change or fade into bureaucratic files. The central government’s involvement signals a broader push to dismantle the racket threatening millions.
